RY 169.88 -1.0542% SHOP 144.59 -0.959% TD 77.85 -0.1667% ENB 59.62 -0.5505% BN 78.53 -0.971% TRI 223.92 -0.2495% CNQ 47.03 -0.0213% CP 102.49 -0.5627% CNR 147.77 -0.8787% BMO 131.32 -0.0685% BNS 78.4 0.0255% CSU 4463.7002 0.6222% CM 90.42 0.6344% MFC 44.91 -1.3184% ATD 77.0 -0.7604% NGT 60.01 -0.4149% TRP 68.0 -2.2989% SU 56.965 -0.4282% WCN 260.14 -0.653% L 176.45 0.7135%
Last update at 2024-11-20T19:32:00Z
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress
Wed 11 Oct 23, 11:00 AMSernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
Wed 13 Sep 23, 11:00 AMSernova Corporation Announces the Appointment of Cynthia Pussinen as CEO
Tue 05 Sep 23, 11:00 AM| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Income before tax | -24.42054M | -6.96554M | -5.32131M | -3.97127M | -3.69863M |
| Minority interest | - | - | - | - | - |
| Net income | -24.53854M | -7.00676M | -5.33543M | -3.96560M | -3.70833M |
| Selling general administrative | 7.83M | 2.29M | 2.48M | 2.00M | 1.47M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.44M | 0.27M | 0.23M | 0.06M | - |
| Ebit | -24.17648M | -6.86595M | -5.22091M | -3.96967M | -3.68892M |
| Ebitda | -23.73648M | -6.59875M | -4.99568M | -3.90820M | -3.62439M |
| Depreciation and amortization | 0.44M | 0.27M | 0.23M | 0.06M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -24.17648M | -6.86595M | -5.22091M | -3.96967M | -3.68892M |
| Other operating expenses | 24.75M | 6.94M | 5.26M | 4.01M | 3.71M |
| Interest expense | 0.12M | 0.06M | 0.09M | 0.00727M | 0.00971M |
| Tax provision | - | - | 0.00000M | - | - |
| Interest income | 0.33M | 0.02M | 0.02M | 0.04M | 0.00781M |
| Net interest income | 0.46M | 0.01M | -0.04743M | 0.03M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.12M | 0.04M | 0.01M | -0.00567M | 0.00971M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 24.75M | 6.94M | 5.26M | 4.01M | 3.71M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | -0.24406M | -0.09958M | -0.10040M | -0.00160M | -0.00971M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -24.42054M | -6.96554M | -5.32131M | -3.97127M | - |
| Net income applicable to common shares | -24.42054M | -6.96554M | -5.32131M | -3.97127M | -3.69863M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Total assets | 22.11M | 52.48M | 29.82M | 5.73M | 5.57M |
| Intangible assets | 0.00032M | 0.52M | 0.72M | 0.92M | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.16M | 0.17M | - | - | - |
| Total liab | 9.59M | 4.88M | 1.75M | 1.58M | 0.69M |
| Total stockholder equity | 12.51M | 47.61M | 28.07M | 4.14M | 4.88M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2.61M | 0.99M | 0.98M | 0.32M | 0.21M |
| Common stock | 110.99M | 110.99M | 74.01M | 44.64M | 41.31M |
| Capital stock | 110.99M | 110.99M | 74.01M | 44.64M | 41.31M |
| Retained earnings | -118.16701M | -79.16949M | -54.74895M | -47.78341M | -42.46210M |
| Other liab | - | - | - | - | - |
| Good will | 0.32M | - | - | - | - |
| Other assets | 0.00000M | 0.22M | 0.21M | - | - |
| Cash | 8.72M | 3.78M | 27.87M | 3.95M | 1.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 9.59M | 4.74M | 1.48M | 0.88M | 0.69M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -8.58571M | -3.50007M | -27.48084M | -3.24680M | -1.79714M |
| Short term debt | 0.14M | 0.14M | 0.12M | 0.03M | 0.00000M |
| Short long term debt | - | - | - | 0.03M | - |
| Short long term debt total | 0.14M | 0.28M | 0.39M | 0.70M | - |
| Other stockholder equity | 19.69M | 15.79M | 8.81M | 7.29M | 6.04M |
| Property plant equipment | - | 0.65M | 0.56M | 0.20M | 0.25M |
| Total current assets | 21.02M | 51.09M | 28.33M | 4.61M | 5.32M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 47.09M | 27.35M | 3.23M | 4.88M |
| Short term investments | 11.08M | 46.00M | - | 0.00000M | 2.01M |
| Net receivables | 1.05M | 1.15M | 0.45M | 0.51M | 0.74M |
| Long term debt | - | - | 0.00000M | 0.70M | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 6.85M | 3.61M | 0.38M | 0.53M | 0.47M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.26M | 0.22M | 0.60M | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.08M | 1.39M | 1.49M | 1.12M | 0.25M |
| Capital lease obligations | 0.14M | 0.28M | 0.39M | - | - |
| Long term debt total | - | 0.14M | 0.28M | 0.70M | 0.00000M |
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Investments | -46.34131M | -0.22878M | 0.99M | -1.02002M | - |
| Change to liabilities | 3.31M | 0.46M | 0.22M | 0.32M | - |
| Total cashflows from investing activities | -46.34131M | -0.22878M | 0.99M | -1.02002M | -0.11066M |
| Net borrowings | -0.16856M | -0.02800M | 0.87M | 4.56M | - |
| Total cash from financing activities | 36.66M | 31.00M | 5.10M | 5.27M | 3.14M |
| Change to operating activities | -0.16381M | 0.14M | 0.63M | -0.67660M | - |
| Net income | -24.42054M | -6.96554M | -5.32131M | -3.97127M | -3.69863M |
| Change in cash | -24.09814M | 23.92M | 2.15M | 0.06M | -0.88817M |
| Begin period cash flow | 27.87M | 3.95M | 1.80M | 1.74M | 2.63M |
| End period cash flow | 3.78M | 27.87M | 3.95M | 1.80M | 1.74M |
| Total cash from operating activities | -14.42140M | -6.84374M | -3.93920M | -4.19239M | -3.91601M |
| Issuance of capital stock | 20.28M | 21.13M | 3.54M | 4.56M | - |
| Depreciation | 0.44M | 0.27M | 0.23M | 0.06M | 0.06M |
| Other cashflows from investing activities | -46.01231M | -0.21155M | 2.00M | -0.99602M | 0.00437M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.19504M | -0.08980M | 0.01M | 0.11M | - |
| Sale purchase of stock | 36.51M | 29.90M | 3.56M | 4.73M | 2.81M |
| Other cashflows from financing activities | 16.55M | 9.90M | 1.65M | 0.71M | 3.14M |
| Change to netincome | 6.61M | -0.66296M | 0.29M | -0.03767M | - |
| Capital expenditures | 0.33M | 0.02M | 1.01M | 0.02M | 0.12M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.95M | 0.52M | 0.86M | -0.24493M | -0.14169M |
| Stock based compensation | 7.45M | 0.22M | 0.68M | 0.88M | 0.53M |
| Other non cash items | -0.83857M | -0.88136M | -0.38888M | -0.91343M | -0.66630M |
| Free cash flow | -14.75040M | -6.86097M | -4.94483M | -4.21639M | -4.03104M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| SVA Sernova Corp |
0.005 2.17% | 0.23 | - | - | - | 26.93 | -11.2729 | |
| FRX Fennec Pharmaceuticals Inc |
0.70 12.30% | 6.39 | 58.90 | 212.77 | 3.27 | 57.98 | 2.14 | 15.89 |
| MDNA Medicenna Therapeutics Corp |
-0.12 7.41% | 1.50 | - | 204.08 | - | 6.92 | -6.1093 | |
| EPRX Eupraxia Pharmaceuticals Inc |
0.61 13.26% | 5.21 | - | - | - | 7.62 | -3.8823 | |
| ONC Oncolytics Biotech Inc |
-0.08 5.41% | 1.40 | - | - | - | 6.21 | -2.4457 |
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
The Stiller Centre, London, ON, Canada, N6G 4X8
| Name | Title | Year Born |
|---|---|---|
| Mr. Frank A. Holler MBA | Exec. Chairman | 1957 |
| Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. | Pres, CEO & Director | NA |
| Mr. David Swetlow C.A, C.A., CPA | Chief Financial Officer | NA |
| Mr. Douglas Maret | Chief Science Officer | NA |
| Mr. Christopher Barnes | VP of Investor Relations | NA |
| Mr. James T. Parsons CPA-CA, MAcc | CFO & Director | 1965 |
| Dr. Modestus Obochi M.B.A., Ph.D. | Chief Business Officer | NA |
| Dr. Frank Shannon M.D. | Vice President of Clinical Development & Regulatory Affairs | NA |
| Mr. Jonathan M. N. Rigby M.B.A., MBA | Executive Chairman | 1968 |
| Mr. David Burke | Vice President of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...